Brought to you by 
Roche licenses Stressgen's HspE7 anti-HPV therapy
16 Feb 2017
Executive Summary
Roche licensed exclusive worldwide rights to Stressgen Biotechnologies' immunotherapeutic HspE7, currently in Phase II clinical trials for recurrent respiratory papillomatosis (RRP) and Phase III for anal dysplasia (both are diseases associated with the human papillomavirus (HPV)).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses Stressgen's HspE7 anti-HPV therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice